SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

Fueled by expansion plans and potential AI/HPC growth, TeraWulf is trending as the community anticipates a possible short squeeze. Discussions revolve around key price levels, analyst price targets, and the stock's potential to follow similar runs seen in the AI data center space. Some investors are noting Google's backing as a key factor for long-term growth.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

Aqua Metals ($AQMS) is trending as traders discuss its potential for a continued squeeze, citing its low float and positioning in the critical metals sector. Some community members are drawing parallels to similar stocks, suggesting further upward momentum, while others caution about the minerals/metals hype potentially nearing its end. The discussion also encompasses the company's potential role in addressing rare earth scarcity, amplifying investor interest.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is surging due to progress on its 800V GaN and SiC power devices for NVIDIA's AI factory computing platforms, sparking excitement about its role in AI infrastructure. The community is closely watching for a potential short squeeze, with many expressing bullish sentiment and targeting higher price levels. Some investors are debating whether to chase the rally or wait for a pullback.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines ($LUNR) is trending as the community focuses on the company's potential for profit and upcoming missions. The stock is experiencing increased attention amid discussions about a possible short squeeze and anticipation of an upcoming earnings report. Bullish sentiment centers around the belief that $LUNR is undervalued, especially compared to other companies in the space sector.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending as traders discuss potential short squeezes and its low float. Community members are pointing to the stock's potential for a breakout, while others caution about its history of dilution and financial standing. The stock is also gaining attention in relation to sympathy plays with other names in the sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders react to a former president's social media posts regarding trade relations with China, specifically related to cooking oil and soybeans. The community is actively discussing the market's sensitivity to these tweets, questioning whether such news warrants the market's reaction and also debating potential market manipulation.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as the Russell 2000 ETF hits new highs, with community members discussing potential catalysts and resistance levels around $250. Bullish sentiment is fueled by the ETF's impressive move from its low of day, leading to speculation about a continued rally. Some traders are taking profits and hedging positions, while others express concerns about overbought conditions and potential pullbacks.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as traders discuss a potential breakout and compare it to $HOOD, focusing on its growth potential and international expansion. Optimism is fueled by technical indicators like bullish candlestick patterns and discussions around options expiration, with some anticipating a significant price increase. Community members are debating whether the stock is undervalued and poised for a rally, while others express concern about recent price action and volatility.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors discuss its potential breakthrough to all-time highs, fueled by a robust e-commerce strategy and AI initiatives like the Sparky shopping assistant. Community members are weighing whether the stock's premium valuation is justified amidst strong fundamentals and growth prospects. Discussions also involve the company's strategic partnerships, including collaborations with OpenAI and Klarna, and their potential impact on Walmart's market position.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to market reactions to escalating trade tensions with China, particularly after a statement regarding potential restrictions on cooking oil imports. Community discussions revolve around the perceived market manipulation and the impact of these trade war escalations on tech stocks. The broader context includes concerns about potential economic consequences and the Federal Reserve's response to these developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bank of America Securities said GoodRx’s long-term outlook will depend on how it adapts to a rapidly evolving prescription drug market, as the Trump administration intensifies efforts to shift pricing away from list prices toward net prices.The firm maintained an ‘Underperform’ rating on GoodRx, saying “the popping of the gross-to-net bubble is a negative for GoodRx’s original business model.” It added that the company’s success will depend on how it navigates this “rapidly evolving market.”The bank’s research arm said it does not “have a strong view at this time” on the potential upside or downside from GoodRx’s reported discussions with the Trump administration about joining the new TrumpRx platform.&nbsp;The initiative, expected to launch next year, aims to let consumers buy brand-name drugs directly from pharmaceutical companies such as Pfizer and Amgen at negotiated insurer-level prices, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us-pharmacies-drug-discounters-are-discussing-trumprx-role-with-administration-2025-10-09/">report</a>.The Trump administration is reportedly pressuring manufacturers and pharmacy benefit managers to abandon list pricing and expand U.S. manufacturing, with steep tariffs threatened for companies that fail to comply. TrumpRx was introduced at a White House event last week as part of that effort to help Americans access cheaper medications, though officials said details are still being finalized.GoodRx CEO Wendy Barnes said that the administration understands that “if we include the pharma direct programs, we also have to find a way to convey competitive cash pricing at retail pharmacies.”Industry groups such as the National Community Pharmacists Association and the National Association of Chain Drug Stores have also been in talks with officials about ensuring that the same discounted prices are available to consumers at local pharmacies.On Stocktwits, retail sentiment for GoodRX was ‘extremely bullish’ amid a 13,400% surge in 24-hour message volume.One user suggested the recent developments might reflect either management preparing for a major move or signaling an upcoming launch, noting the stock’s steady trend of higher highs and lows and arguing that low-cost healthcare offerings make sense in today’s market.&nbsp;<stembedurl>https://stocktwits.com/HOSTILE/message/631753526</stembedurl>Another user commented that investors should stay patient, expressing confidence that GoodRx would eventually strike a deal likely to attract millions of new customers, while adding that even a pullback to support levels would present limited downside risk.<stembedurl>https://stocktwits.com/GSTX7/message/631723527</stembedurl><a href="https://stocktwits.com/symbol/GDRX">GoodRX’s stock</a> has declined 0.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the GoodRx Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

GoodRx Stock Buzzes As TrumpRx Drug Pricing Shake-Up Draws BofA Warning On Core Business Model

BofA Securities said GoodRx’s future hinges on how it adapts to the Trump administration’s TrumpRx plan and the broader shift toward net drug pricing.

Equity

Hims & Hers Expands Personalized Care Access Via Telehealth Platform

HIMS expands its AI-powered telehealth platform, boosting personalized care and eyeing international growth in 2026.

GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

GoodRx Holdings, Inc. (Nasdaq: GDRX) (GoodRx or the Company), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after...

Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%

AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.

Amgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the current list price via its direct-to-patient program in the U.S.The program, called AmgenNow, follows the Trump Administration’s push to lower drug prices in the U.S. Repatha will be available through the platform at a monthly cost of $239, Amgen <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/amgen-makes-repatha-available-through-amgennow-a-direct-to-patient-program-in-the-us-302575486.html">said</a>. The company noted that the program is open to all patients, including those who are uninsured or in high-deductible health plans or prefer to pay with cash or out of pocket.The company also noted that the new direct-to-patient price is the lowest among the economically developed countries and is being offered solely to U.S. patients.Amgen’s Repatha is indicated for lowering low-density lipoprotein cholesterol, commonly referred to as “bad” cholesterol.Shares of the company traded over 1% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.Amgen announced on Monday that it intends to make its direct-to-consumer platform accessible via the TrumpRx website, which was announced by the President last week and is slated for launch next year. The site will enable American consumers to purchase prescription drugs from pharmaceutical companies at a discount.In the second quarter of 2025, Repatha sales increased 31% year-over-year to $696 million, driven by 36% volume growth. This represented nearly 7.6% of the company’s overall revenue in the period.The announcement comes on the heels of President Trump sending letters to 17 drugmakers, including Amgen, in July, demanding that they lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations. Amgen announced on Monday that it would add other drugs to its AmgenNow platform.Separately, the medication savings platform GoodRx (GDRX) also said on Monday that patients can use the platform to access Repatha for $239 at more than 70,000 pharmacies U.S.-wide.AMGN stock is up by 14% this year but down by about 7% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

Amgen To Sell Cholesterol Drug For Approximately 60% Discount 

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 

Hims & Hers Expands AI and Technology Focus to Advance Digital Care

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

U.S. equities edged lower in Monday’s midday trade as investors turned cautious ahead of Federal Reserve Chair Jerome Powell’s speech at the Jackson Hole symposium on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.08% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.19%.Here are the top stocks making the biggest moves in Monday’s midday trade:<a href="https://stocktwits.com/symbol/DAY">Dayforce Inc. (DAY)</a>Dayforce shares skyrocketed 26% in Monday’s midday trade after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/thoma-bravo-eyes-takeover-of-hr-software-firm-dayforce-report/chsaxunRdQJ">reports</a> suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.<a href="https://stocktwits.com/symbol/DAY">DAY stock</a> is down 8% year-to-date.<a href="https://stocktwits.com/symbol/APLD">Applied Digital Corp. (APLD)</a>Applied Digital shares gained over 14% in Monday’s midday trade after it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/this-data-center-stock-doubled-in-2025/chsOWqERdX9">announced</a> plans to begin construction of its next-generation $3 billion AI campus, Polaris Forge 2, in September.<a href="https://stocktwits.com/symbol/APLD">APLD stock</a> is up 111% year-to-date.<a href="https://stocktwits.com/symbol/GDRX">GoodRx Holdings Inc. (GDRX)</a>GoodRx shares surged over 35% in Monday’s midday trade after Novo Nordisk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cuts-ozempic-cost-to-499-dollars-per-month-for-self-paying-patients/chsOfKDRdXE">announced</a> a collaboration with the drug savings platform to provide self-paying eligible type 2 diabetes patients with access to Ozempic at $499.<a href="https://stocktwits.com/symbol/GDRX">GDRX stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/FSLR">First Solar Inc. (FSLR)</a>First Solar shares surged nearly 9% in Monday’s midday trade as investors cheered the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/solar-incentives-treasury-clears-the-air-fslr-run-enph-nee-stocks-in-focus/chsOJX1RdQy">clarity offered</a> by the U.S. Treasury Department and the Internal Revenue Service regarding wind and solar incentives. Shares of other clean energy companies, like SolarEdge Technologies Inc. (SEDG), Sunrun Inc. (RUN), Enphase Energy Inc. (ENPH), and NextEra Energy Inc. (NEE), also rose.<a href="https://stocktwits.com/symbol/FSLR">FSLR stock</a> is up 23% year-to-date.<a href="https://stocktwits.com/symbol/WULF">TeraWulf Inc. (WULF)</a>TeraWulf shares surged more than 11% in Monday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/terawulf-launches-400-million-convertible-note-offering/chsO7yLRdQx">announced</a> plans to raise $400 million through a private offering of convertible senior notes due in 2031. Alphabet Inc.’s (GOOG/GOOGL) Google also extended its backstop to $3.2 billion from $1.8 billion, with its stake in the company increasing to nearly 14%.<a href="https://stocktwits.com/symbol/WULF">WULF stock</a> is up 76% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-warns-investors-be-prepared-goldilocks-dominating-equity-markets/chsOiYdRdXg">JPMorgan Warns Investors To Brace For Incoming Volatility, Says ‘Goldilocks’ Narrative Still Dominating Markets: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Dayforce, Applied Digital, GoodRx, First Solar, TeraWulf: Stocks Making The Biggest Moves Today

Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.

Danish drugmaker Novo Nordisk (NVO) has announced that it will allow self-paying eligible type 2 diabetes patients access to its Ozempic for $499 per month starting Monday via multiple platforms, including drug savings platform GoodRx (GDRX).The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost. The offer will also be available through the company’s online pharmacy, NovoCare, as well as the drug’s official website.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-full-year-guidance/cho9UwAR5yE">NVO</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. Shares of the company traded 5% higher on Monday morning at the time of writing.The offer comes as the company battles the compounding of its blockbuster medicines. Last month, Novo lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and Ozempic for the second half of the year. While the U.S. Food and Drug Administration has prohibited mass compounding for the active component in Wegovy and Ozempic called Semaglutide, unsafe and unlawful mass compounding has continued, the company said, citing its market research.“We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many. This is why we felt it was important to make Ozempic, the GLP-1 with the broadest range of FDA-approved indications for adults with type 2 diabetes, more affordable to those without insurance who deserve the real thing," <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916418">said</a> Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc.As part of Novo’s collaboration with GoodRx, self-paying patients can get all strengths of both Wegovy and Ozempic for $499 per month through the GoodRx platform. Eligible patients can use GoodRx to self-pay for Ozempic and Wegovy pens for $499 per month at over 70,000 retail pharmacies nationwide, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-announces-collaboration-novo-nordisk-expand-access">said</a>. Shares of <a href="https://stocktwits.com/symbol/GDRX">GDRX </a>traded 31% higher following the news.While NVO stock is down by 37% this year, GDRX is up by 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT">LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients

The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost.

Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates

GoodRx (GDRX) delivered earnings and revenue surprises of -10.00% and -1.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx Holdings Inc - Ordinary Shares - Class A

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$4.14
Prev Close	$4.16
Open	$4.04
Dividend Yield	0.00%
50-Day Moving Average	$4.21
Beta	1.54
Avg. Volume	2.44M
PE Ratio	44.83

52-Week High	$7.11
52-Week Low	$3.31
Market Capitalization	$1.45B
EPS (Annual)	$0.0418
Price to Book	2.28
Revenue Per Employee	$1.07M
Enterprise Value/EBITDA	N/A

GDRX
GoodRx Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GDRX News

GDRXGoodRx Holdings Inc